12:00 AM
 | 
Aug 14, 2000
 |  BC Week In Review  |  Company News  |  Deals

Biogen, Genovo Inc., Targeted Genetics deal

TGEN will acquire gene therapy company Genovo for 6.63 million TGEN shares, valued at $67 million. Genovo has adeno-associated virus (AAV) vector gene therapies in development to treat hyperlipidemia, atherosclerosis and hemophilia, and associated intellectual property covering AAV and other viral vectors....

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >